이뮨온시아

424870KOSDAQ자연과학 및 공학 연구개발업

56.3 / 100

Reference Date: 2026-06-10

Financial Score18.5 / 40

News Sentiment18.8 / 25

Momentum7.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 38.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Imunovia specializes in developing antibody-based immunotherapy drugs, with key assets including Anti-PD-L1, Anti-CD47, and Anti-LAG-3 monoclonal antibodies. The company is conducting Phase 2 trials for IMC-001 in NK/T cell lymphoma and TMB-High solid tumors, aiming for domestic commercialization and the development of a global blockbuster drug.

Number of Employees

22people

Average Salary

103.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

13.38Industry Average 3.240.0Point

4.1x industry avg (risky)

ROE

-114.40Industry Average -32.093.5Point

3.6x industry avg (excellent)

Debt Ratio

1.66Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 3.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

0.0 / 4

Detailed News Sentiment

5 totalPositive 4Neutral 0Negative 1Average Sentiment Score 75

Negative
[메자닌 투자파일] 이뮨온시아, 불확실 LO 의존…CB 카드 꺼내나
이뮨온시아의 유상증자 자금 감소로 인해 면역항암제 상업화 비용 재조정이 필요해지며, 시장 불확실성이 증가하고 있다.
Positive
이뮨온시아 "삼중음성유방암 1b상서 항종양 효과"
이뮨온시아의 면역항암제 IMC-002가 ASCO에서 진행성 삼중음성유방암 임상 1b상에서 긍정적인 항종양 효과를 보여주며 주가 상승 기대.
Positive
이뮨온시아 "IMC-002 1b상서 항종양 효과 입증…질병통제율 75%...
이뮨온시아의 IMC-002가 TNBC 임상 1b상에서 높은 질병 통제율을 보여 긍정적인 결과를 발표했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 4,165Won52-week high 15,38052-week low 4,165

1-month return0.0Point

1m -38.57% (strong drop)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

8 totalPositive 1Neutral 7Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-28
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-27
Neutral주식등의대량보유상황보고서(일반)2026-05-27
Neutral증권발행실적보고서2026-05-21
Neutral증권발행결과(자율공시)2026-05-21